Indoco Remedies Limited (INDOCO) — Announcement Announcement

· NSE Neutral
📢 Key Event
Indoco Remedies receives EU GMP certification for Baddi Plant III facility
💡 Investor Takeaway
The certification validates manufacturing quality, enhancing investor confidence in Indoco's export growth potential and regulatory compliance.

Indoco Remedies announced that its Baddi Plant III facility in Himachal Pradesh received EU GMP certification from the German Health Authority (Berlin) following an inspection conducted between April 22 and April 27, 2026. The certification confirms compliance with EC Directive manufacturing standards, reinforcing the company's quality credentials for global markets. This achievement strengthens Indoco's position as a regulated manufacturer with USFDA and UK-MHRA-approved facilities, supporting its export-oriented formulation business and expanding regulatory acceptance for its product portfolio across therapeutic segments.

📄 View Original Announcement (PDF)

About Indoco Remedies Limited (INDOCO)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹2,075.91 Cr P/E: -142.3

View full INDOCO stock details →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.